Akums Drugs and Pharmaceuticals Ltd has fixed Friday, July 3, 2026, as the record date to determine shareholder eligibility for a final and special dividend of ₹3 per equity share. The Board of Directors recommended the payout at its meeting held on May 14, 2026, for the financial year ended March 31, 2026. The dividend comprises a final dividend of Re 1 and a special dividend of ₹2, aggregating to ₹3 per share, which represents a 150% payout on the face value of ₹2 per share. The distribution is subject to the approval of members at the ensuing Annual General Meeting (AGM).

The 22nd AGM of the company is scheduled to be held on Friday, July 10, 2026, at 11:00 A.M. IST through Video Conferencing (VC) and Other Audio Visual Means (OAVM). The meeting will be conducted in compliance with the provisions of the Companies Act, 2013, and relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (SEBI). The Notice of the AGM and the Integrated Annual Report for the Financial Year 2025-26 will be sent electronically to members and made available on the company’s website.

If approved by shareholders, the final and special dividend will be paid within 30 days from the date of conclusion of the AGM. The payment will be made exclusively through electronic mode to shareholders whose names appear in the Register of Members or the Register of Beneficial Owners maintained by the Depositories as on the record date. The company has advised members to ensure their bank details are updated with their Depository Participants to avoid delays in receiving the dividend.

Dividend Details

Key Meeting Dates

Akums Drugs and Pharmaceuticals Limited has scheduled two investor and analyst meets for June 15, 2026, to engage with the investment community. The company will participate in the India Conclave Conference and the Small-Cap Investor Conference, both commencing at 09:00 A.M. (IST). These meetings provide a platform for the company to present its business outlook and operational performance directly to market participants.

The disclosure was made to the National Stock Exchange of India Ltd. and BSE Limited pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Akums Drugs & Pharma clarified that no unpublished price sensitive information will be shared during these interactions.

The meetings are categorized as group meets and will be held in two different locations. The schedule details are as follows:

The company noted that the schedule may be subject to change due to exigencies on the part of the host or the company. A copy of the disclosure has been updated on the official website of Akums Drugs and Pharmaceuticals Limited. Dharamvir Malik, Company Secretary & Compliance Officer, authorized the filing on June 10, 2026.